Nicole MacMillan, Cardiovascular Roundtable
The introduction of novel oral anticoagulants to reduce the risk of stroke and systemic embolism in atrial fibrillation (AF) patients was hotly anticipated when the first of three new drugs hit the market in October 2010, and continues to be a frequent topic of discussion in industry journals and newsletters. While the Roundtable has covered the introduction of these new drugs in the past, we wanted to provide a more comprehensive overview of the current state of affairs, as well as what these new drugs could mean for those treating AF.
The three novel oral anticoagulants, dabigatran (Pradaxa, Boehringer Ingelheim), rivaroxaban (Xarelto, Bayer/ Johnson & Johnson) and apixaban (Eliquis, Pfizer/ Bristol-Myers Squibb), have been expected to revolutionize stroke prevention in AF patients, offering physicians the chance to take AF patients off warfarin.
What’s going on with novel oral anticoagulants for AF?
Megan Tooley, Cardiovascular Roundtable
Patients with a history of atherosclerotic ischemic stroke should be considered to be at high risk for subsequent cardiovascular disease (CVD), in particular, coronary heart disease (CHD), according to a new joint scientific statement released by the American Heart Association (AHA) and American Stroke Association (ASA).
These recommendations—the first U.S. guidelines to include stroke as a risk factor for coronary events—may require re-evaluation of current risk prediction algorithms and significantly increase the population of patients considered to be at high CV risk.
Add stroke to list of CVD risk factors, new AHA/ASA statement recommends
A recent analysis of the utilization of carotid artery stenting (CAS) among Medicare beneficiaries indicates mortality rates are lower for operators who perform a higher volume of procedures per year compared to those who handle fewer cases. The findings suggest operator experience is associated with 30-day patient mortality, but generally raise questions regarding the effectiveness of CAS in a real-world setting.
Operator Experience Matters With Carotid Artery Stenting